Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd. (BWAY) generates a steady flow of news centered on its Deep TMS™ neurostimulation technology, regulatory developments, clinical research, and financial performance. As a company focused on noninvasive brain stimulation for mental health disorders, BrainsWay frequently announces updates related to major depressive disorder, obsessive-compulsive disorder, smoking addiction, and emerging indications such as Alcohol Use Disorder.
News items for BrainsWay often cover FDA clearances and label expansions, including accelerated Deep TMS protocols for MDD and indications that extend treatment to adolescent patients aged 15 to 21. The company also reports on payer coverage decisions, such as new or expanded medical policies from insurers that reimburse Deep TMS depression therapy for adults and adolescents, and coverage of its SWIFT™ accelerated protocol. These updates provide insight into how access to Deep TMS is evolving across different patient populations and geographies.
Investors following BWAY can also expect clinical research and grant-related announcements, including NIH-funded studies evaluating accelerated Deep TMS protocols for Alcohol Use Disorder and stimulant use disorders, as well as company-sponsored trials using the Deep TMS 360™ multichannel system. In addition, BrainsWay issues news on strategic investments, such as its minority-stake investment in Neurolief and stakes in mental health providers, and on financial results that highlight revenue trends, installed base growth, and multi-year customer agreements.
The BrainsWay news page on Stock Titan aggregates these updates so readers can track regulatory milestones, payer coverage changes, clinical trial progress, strategic partnerships, and quarterly financial disclosures related to BWAY stock. This makes it a useful reference for monitoring how the company’s Deep TMS platform and broader neuromodulation strategy are developing over time.
BrainsWay Ltd. (NASDAQ: BWAY) reported Q2 2020 revenues of $4.8 million, down 15% from Q2 2019 due to COVID-19-related disruptions. The installed base of Deep TMS systems rose 24% year-over-year to 567 systems, with significant reimbursement progress made for major depressive disorder treatments. The company achieved a 79% gross margin and reduced operating expenses to $4.0 million, down from $7.0 million in the previous year, leading to a smaller operating loss of $0.2 million compared to $2.7 million in 2019.
BrainsWay Ltd. (NASDAQ: BWAY) will announce its Q2 2020 financial results on August 12, 2020, before U.S. markets open. A conference call will take place at 8:30 AM ET to discuss the results and business updates. BrainsWay specializes in non-invasive treatments for brain disorders through its Deep TMS technology, which has FDA approval for treating major depressive disorder and obsessive-compulsive disorder. The company is currently conducting clinical trials for various neurological and psychiatric disorders. Forward-looking statements involve risks and uncertainties.